Cardiac and Vascular Responses to Creatine Supplementation in Elderly Men

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-09

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the impact of creatine supplementation alone or in combination with a moderate session of physical activity on vascular reactivity and heart hemodynamics in elderly men.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Creatine Monohydrate Supplementation and Vascular Endothelial Health

NCT05014659

Endothelial Dysfunction Oxidative Stress

COMPLETED NA

The Effect of NADPH Oxidase and Creatine Supplementation on Microvascular Blood Flow Regulation

NCT06018480

Endothelial Dysfunction

COMPLETED NA

Effects of Combinations of Performance-enhancing Supplements on Exercise Performance

NCT05354999

Healthy

UNKNOWN NA

Effects of Creatine Supplementation on Renal Function

NCT00465140

Renal Insufficiency

COMPLETED NA

Load and Hold: Impact of 7-Day Creatine Monohydrate Loading on Breath-Hold Cycling Performance

NCT07233707

Healthy

ENROLLING_BY_INVITATION NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Before beginning baseline testing, subjects' vitals will be measured (heart rate, blood pressure) in order to ensure that they are safe to participate in the submaximal exercise test. Subjects will also complete the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) to screen for cardiovascular risk factors. Information about physical activity level, medical history, and creatine supplementation use history will also be acquired. After anthropometric measurements, subjects will be asked to lay down in a hospital-type bed for measuring heart function and vascular responses at rest.

For measures of heart function, a non-invasive bioimpedance device will be used. Five ECG electrodes will be placed on chest and neck areas that will continuously collect information about heart rate, stroke volume, contractility index, ejection fraction and systemic vascular resistance. Vascular responses will be assessed using a non-invasive arterial pulse wave velocity equipment. This test uses four blood pressure cuffs placed on the wrists and calves, which, after 10 seconds inflation, are able to calculate an index of stiffness.

After resting values are collected, the cuffs will be removed, and subjects will be asked to walk on a treadmill at 6 km/h (3.1mph) and 5% grade for 10 minutes. During the treadmill walking, subjects will have their heart monitored using the non-invasive bioimpedance device with the ECG attached to their chest and neck. After 10 minutes have passed, subjects will be asked to step down from the treadmill and lay down on in the same hospital type bed.

At this time, the four blood pressure cuffs will be placed again on the wrists and calves to measure the vascular responses. We plan on performing two arterial stiffness measurements, after 10 and 20 minutes of the treadmill walking. After 20 minutes of monitoring while lying in bed, subjects will be disconnected from all ECGs and blood pressure cuffs.

Randomization in one of the three groups will occur using a computer generated sequence. The groups will have 15 subjects each and will consist of creatine supplementation, placebo supplementation (maltodextrin) and control (no supplementation). After randomization, subjects will receive their assigned packages containing the supplementation supplies corresponding to their group allocation (creatine or placebo). After 7 days of 20g/day supplementation, subjects will be asked to come back to the testing center for a repeat of the exercise test and corresponding heart monitoring and vascular responses before and after the treadmill walk.

To ensure good compliance with supplementation, subjects will receive daily text messages with reminders about their dose ingestion. The 20g/day will be divided in 4 dosages of 5g each that should be taken with water or other liquids throughout the day (breakfast, lunch, afternoon and evening).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Function and Hemodynamics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Creatine Monohydrate Supplementation

Blinded subjects are instructed to ingest 20g of creatine monohydrate for 7 days divided into 4 dosages of 5g each that should be taken with water or other liquids throughout the day (breakfast, lunch, afternoon and evening).

Group Type EXPERIMENTAL

Creatine Monohydrate

Intervention Type DIETARY_SUPPLEMENT

Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.

Maltodextrin Supplementation

Blinded subjects are instructed to ingest 20g of maltodextrin for 7 days divided into 4 dosages of 5g each that should be taken with water or other liquids throughout the day (breakfast, lunch, afternoon and evening).

Group Type PLACEBO_COMPARATOR

Maltodextrin

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin powder, 4 separate 5g doses per day for 7 days.

Control

Participants in the control group do not receive a supplement (creatine or placebo) to ingest over the 7 day period.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Creatine Monohydrate

Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin

Maltodextrin powder, 4 separate 5g doses per day for 7 days.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males
* 55-80 years old
* No restrictions based on race, ethnicity, or socioeconomic status

Exclusion Criteria

* Females
* \<55 or \>80 years old
* Individuals with known serious cardiac pathology
* Individuals with known serious kidney pathology
* Appropriate for moderate intensity exercise (screening using PAR-Q+)
* Individuals currently consuming or had consumed creatine supplement within 3 months prior to screening

Minimum Eligible Age

55 Years

Maximum Eligible Age

80 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes